BPC-157 half-life and pharmacokinetics: what the evidence does and does not show

What animal studies suggest

Published preclinical literature, most of it from the Zagreb group, contains some pharmacokinetic observations in rodent models. The primary findings are:

Preclinical PK estimates from the published literature. None of these values has been validated in a human study with a calibrated assay.^[1],[2]

Why rat pharmacokinetics cannot be applied to humans

Extrapolating pharmacokinetic parameters from rats to humans is notoriously unreliable, particularly for peptides. Key reasons include:

• Proteolytic enzyme differences: Rats and humans differ in the activity and distribution of serum and tissue proteases that degrade short peptides. A peptide that is rapidly cleared in rats may be cleared at a different rate in humans, and vice versa.
• Body surface area and allometric scaling: Simple body-weight scaling systematically underperforms for peptides, which are often cleared by proteolysis rather than renal filtration or hepatic oxidation.
• Assay specificity: Short peptides are difficult to measure in complex biological matrices. Older preclinical PK estimates may reflect the limits of the assay rather than true plasma concentrations of intact BPC-157.
• Route of administration: Most preclinical efficacy studies used intraperitoneal injection, a route that has no clinical equivalent. Subcutaneous and oral routes behave differently, and cross-route comparisons are not straightforward.

Gastric stability is not the same as oral bioavailability

BPC-157 is described as stable in gastric acid, meaning it resists degradation at low pH in vitro. This is sometimes presented by proponents as evidence that oral administration is viable. The inference is flawed for two reasons:

1. Intestinal absorption is a separate process from gastric stability. For a peptide to be absorbed orally, it must cross the intestinal epithelium, either via transcellular or paracellular routes. Most peptides of 15 amino acids or larger have poor intestinal permeability unless they use specific transporter systems. Whether BPC-157 has access to any such transporter has not been characterized.
2. Stability in simulated gastric fluid (pH 1.2) differs from the full gastrointestinal environment. The small intestine presents pancreatic proteases, brush-border peptidases, and bile salts. A peptide stable in acid may be rapidly cleaved in the intestinal lumen or during transcellular passage.

The assumption that gastric stability predicts meaningful oral bioavailability in humans is not supported by pharmacokinetic data for BPC-157. It remains an open question.

Routes studied in preclinical experiments

Published rodent studies have used three primary administration routes, none of which corresponds to a formally validated human dosing strategy:

• Intraperitoneal (IP): The most common route in rodent experiments. IP injection is not used as a therapeutic route in humans.
• Subcutaneous (SC): Used in a subset of studies. SC is a clinically plausible route, but no human absorption or bioavailability data exist for BPC-157 by this route.
• Intragastric / oral: Used in gastric protection and IBD models. As discussed above, oral activity in rodents does not establish oral bioavailability in humans.^[1]

Summary of knowledge gaps

For a therapeutic to be dosed safely and rationally in humans, pharmacokinetic characterization is essential. For BPC-157, the following fundamental PK parameters are unknown:

• Half-life after any route of administration in humans
• Oral bioavailability
• Subcutaneous bioavailability and absorption rate
• Volume of distribution
• Plasma protein binding
• Metabolic pathways and active metabolite profile
• Renal and hepatic elimination fractions
• Effect of age, sex, body composition, renal function, or hepatic function on clearance

Until Phase I pharmacokinetic studies are conducted and published in humans, any dosing recommendation for BPC-157 lacks a rational pharmacokinetic foundation. This includes the dose ranges and schedules described on vendor websites, in online communities, and in social media. None of those recommendations is derived from validated human PK data.